Market closed
Coherus BioSciences/$CHRS
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Coherus BioSciences
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
Ticker
$CHRS
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
235
Website
CHRS Metrics
BasicAdvanced
$132M
-
-$0.00
0.69
-
Price and volume
Market cap
$132M
Beta
0.69
52-week high
$2.65
52-week low
$0.66
Average daily volume
2M
Financial strength
Current ratio
2.11
Quick ratio
1.505
Long term debt to equity
-300.671
Total debt to equity
-300.671
Interest coverage (TTM)
-3.63%
Management effectiveness
Return on assets (TTM)
-14.03%
Return on equity (TTM)
0.41%
Valuation
Price to revenue (TTM)
0.429
Price to book
-1.51
Price to tangible book (TTM)
-0.93
Price to free cash flow (TTM)
-2.064
Growth
Revenue change (TTM)
44.19%
Earnings per share change (TTM)
-99.84%
3-year revenue growth (CAGR)
-5.76%
3-year earnings per share growth (CAGR)
-89.17%
What the Analysts think about CHRS
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Coherus BioSciences stock.
CHRS Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
CHRS Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
CHRS News
AllArticlesVideos
Coherus Management to Participate at the 45th Annual TD Cowen Health Care Conference
GlobeNewsWire·2 days ago
Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025
GlobeNewsWire·2 months ago
Coherus BioSciences: Shedding Pegfilgrastim To Fuel Ongoing Development
Seeking Alpha·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Coherus BioSciences stock?
Coherus BioSciences (CHRS) has a market cap of $132M as of February 26, 2025.
What is the P/E ratio for Coherus BioSciences stock?
The price to earnings (P/E) ratio for Coherus BioSciences (CHRS) stock is 0 as of February 26, 2025.
Does Coherus BioSciences stock pay dividends?
No, Coherus BioSciences (CHRS) stock does not pay dividends to its shareholders as of February 26, 2025.
When is the next Coherus BioSciences dividend payment date?
Coherus BioSciences (CHRS) stock does not pay dividends to its shareholders.
What is the beta indicator for Coherus BioSciences?
Coherus BioSciences (CHRS) has a beta rating of 0.69. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.